Skip to main content
Good News

Cleveland Clinic CRISPR Trial Cuts Bad Cholesterol 52%

South Jersey NewsBeat
South Jersey NewsBeatAuthor
Published
Reading time1 min
Share:
Cleveland Clinic CRISPR Trial Cuts Bad Cholesterol 52%

CLEVELAND, Ohio — A single infusion of a CRISPR gene-editing therapy lowered dangerous cholesterol by 52% in patients who remained free of side effects 12 months after treatment, according to Phase 1 human trial results reported by the Cleveland Clinic in Ohio. The findings, first reported by Good News Network, mark an early but significant milestone in the effort to treat high cholesterol with a one-time intervention rather than daily medication.

The trial tested a gene-editing approach built on CRISPR-Cas9, the widely studied molecular tool that allows scientists to alter specific sequences of DNA. In this case, the therapy was delivered as a single infusion and produced a sustained reduction in what is commonly called bad cholesterol, with the effect still measurable a full year later. Participants experienced no side effects, according to the clinic's report.

Phase 1 trials are designed primarily to establish safety and tolerability in a small group of participants, not to prove broad effectiveness. The 52% reduction and the 12-month durability observed here therefore represent preliminary signals that will require confirmation in larger, later-stage studies before the therapy could be considered for widespread clinical use.

For patients and clinicians, the appeal of a one-time treatment is substantial. Statins and other cholesterol-lowering drugs depend on consistent daily adherence, and many people struggle to maintain those regimens over years. A therapy that achieves a durable reduction after a single dose could reshape how cardiovascular risk is managed, though experts caution that long-term safety monitoring remains essential for any permanent genetic intervention.

The Cleveland Clinic's announcement adds to a growing body of research exploring CRISPR-Cas9 beyond rare genetic disorders and into common chronic conditions. The trial's results were reported by Good News Network, which highlighted the combination of efficacy, durability, and tolerability observed in the Phase 1 cohort.

Additional details, including the number of participants enrolled and the specific cholesterol measurements recorded, were not included in the initial report. Further peer-reviewed publication and subsequent trial phases will be necessary to determine whether the approach can deliver on its early promise.

Share:

Related Stories

Prairie Village Rallies to Replace Teen's Stolen Gear
Good News

Prairie Village Rallies to Replace Teen's Stolen Gear

After roughly $20,000 in landscaping equipment was stolen from Sonny Gallardo's Prairie Village business, a GoFundMe raised $37,000 to replace it all. The theft struck before Halloween while the teen was still securing insurance.

11/20/2026
South Jersey NewsBeat
Server Guards $20,000 Left in Bedok Cafe
Good News

Server Guards $20,000 Left in Bedok Cafe

A coffee shop server in Bedok protected a bag holding $20,000 in cash during a Saturday dinner rush, and its owner — a noodle manufacturer who had hurried off to a friend's wake — returned at 11pm to find everything intact. Lau Guat Toh plans to keep her $200 reward as a souvenir.

11/20/2026
South Jersey NewsBeat
WOND - banner